Abstract
SummaryTo institute early prevention of the common CNS neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Disease and Vascular Cognitive Disorders, cost‐effective, non‐invasive early diagnostic biomarkers are essential. Early detection of these diseases is critical given the growing evidence that new therapies will only be effective in pre‐symptomatic or prodromal stages of the degenerative process. Retinal imaging by spectral domain optical coherence tomography is currently used to evaluate morphological neurodegenerative changes caused by ophthalmic disease. Evidence suggests that this technique may also provide a biomarker in AD and PD, revealing changes in the retinal nerve fibre layer that correlate with cortical thinning and possibly prior to emergence of clinical symptoms. This presentation will up‐date the evidence supporting the use of non‐invasive retinal imaging as a pre‐symptomatic prognostic biomarker of CNS neurodegenerative disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
